Legal & General Group Plc Has $3.85 Million Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)

Legal & General Group Plc reduced its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 8.5% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 97,804 shares of the company's stock after selling 9,121 shares during the quarter. Legal & General Group Plc owned approximately 0.11% of CRISPR Therapeutics worth $3,850,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in CRSP. Magnetar Financial LLC acquired a new position in shares of CRISPR Therapeutics in the fourth quarter valued at $359,000. Capital Market Strategies LLC acquired a new position in CRISPR Therapeutics in the 4th quarter valued at about $461,000. Vanguard Group Inc. raised its holdings in CRISPR Therapeutics by 0.6% in the 4th quarter. Vanguard Group Inc. now owns 1,735,998 shares of the company's stock valued at $68,329,000 after acquiring an additional 10,579 shares during the period. KBC Group NV lifted its position in CRISPR Therapeutics by 2,047.4% during the fourth quarter. KBC Group NV now owns 60,514 shares of the company's stock worth $2,382,000 after acquiring an additional 57,696 shares during the last quarter. Finally, Raymond James Financial Inc. bought a new stake in shares of CRISPR Therapeutics during the fourth quarter worth approximately $3,231,000. 69.20% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, General Counsel James R. Kasinger sold 2,850 shares of CRISPR Therapeutics stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total value of $120,897.00. Following the completion of the transaction, the general counsel now directly owns 77,530 shares of the company's stock, valued at approximately $3,288,822.60. This trade represents a 3.55 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO Julianne Bruno sold 1,198 shares of the firm's stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total value of $50,819.16. Following the sale, the chief operating officer now directly owns 8,263 shares of the company's stock, valued at $350,516.46. This represents a 12.66 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 32,381 shares of company stock valued at $1,608,243 over the last ninety days. 4.10% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

CRSP has been the subject of several research reports. Bank of America dropped their price target on CRISPR Therapeutics from $98.00 to $85.00 and set a "buy" rating for the company in a report on Tuesday, January 7th. Needham & Company LLC restated a "buy" rating and issued a $84.00 price target on shares of CRISPR Therapeutics in a research note on Wednesday, April 9th. The Goldman Sachs Group lowered their price target on shares of CRISPR Therapeutics from $66.00 to $57.00 and set a "neutral" rating on the stock in a research report on Thursday, February 13th. Barclays boosted their price objective on shares of CRISPR Therapeutics from $55.00 to $56.00 and gave the company an "equal weight" rating in a report on Wednesday, February 12th. Finally, Evercore ISI raised shares of CRISPR Therapeutics from an "in-line" rating to an "outperform" rating and raised their target price for the stock from $60.00 to $99.00 in a report on Friday, February 14th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $73.11.

CRISPR Therapeutics Price Performance

Shares of CRISPR Therapeutics stock opened at $39.23 on Wednesday. CRISPR Therapeutics AG has a fifty-two week low of $30.04 and a fifty-two week high of $67.88. The company's 50 day moving average price is $40.74 and its two-hundred day moving average price is $43.65. The firm has a market capitalization of $3.36 billion, a P/E ratio of -8.98 and a beta of 1.85.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last announced its quarterly earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. On average, analysts expect that CRISPR Therapeutics AG will post -5.16 earnings per share for the current year.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

Want to see what other hedge funds are holding CRSP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.